Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer

被引：0
|
作者：
Yue Xi
Ting Li
Yun Xi
Xinyi Zeng
Ying Miao
Rui Guo
Min Zhang
Biao Li
机构：
[1] Ruijin Hospital,Department of Nuclear Medicine
[2] Shanghai Jiao Tong University School of Medicine,Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics
[3] Collaboration Innovation Center for Molecular Imaging of Precision Medicine,undefined
[4] Ruijin Center,undefined
[5] National Research Center for Translational Medicine at Shanghai,undefined
[6] Ruijin Hospital,undefined
[7] Shanghai Jiao Tong University School of Medicine,undefined
来源：
Cancer Cell International | / 22卷
关键词：
Triple-negative breast cancer; hENT1; miR-143; Combination therapy; Gemcitabine resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143
    An, Qing
    Zhou, Liyang
    Xu, Nan
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 103 : 415 - 420
  • [32] Triple-negative metastatic/recurrent breast cancer: Treatment with paclitaxel/carboplatin combination chemotherapy
    Chia, J. W.
    Ang, P.
    See, H.
    Wong, Z.
    Soh, L.
    Yap, Y.
    Wong, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Emerging treatment approaches for triple-negative breast cancer
    Capuozzo, Maurizio
    Celotto, Venere
    Santorsola, Mariachiara
    Fabozzi, Antonio
    Landi, Loris
    Ferrara, Francesco
    Borzacchiello, Assunta
    Granata, Vincenza
    Sabbatino, Francesco
    Savarese, Giovanni
    Cascella, Marco
    Perri, Francesco
    Ottaiano, Alessandro
    MEDICAL ONCOLOGY, 2023, 41 (01)
  • [34] Treatment options for patients with triple-negative breast cancer
    Santana-Davila, Rafael
    Perez, Edith A.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
  • [35] Current approaches in treatment of triple-negative breast cancer
    Wahba, Hanan Ahmed
    El-Hadaad, Hend Ahmed
    CANCER BIOLOGY & MEDICINE, 2015, 12 (02) : 106 - 116
  • [36] Atezolizumab in the treatment of metastatic triple-negative breast cancer
    Perez-Garcia, Jose
    Soberino, Jesus
    Racca, Fabricio
    Gion, Maria
    Stradella, Agostina
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (09) : 981 - 989
  • [37] Systemic treatment strategies for triple-negative breast cancer
    Yadav, Budhi Singh
    Sharma, Suresh C.
    Chanana, Priyanka
    Jhamb, Swaty
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (02): : 125 - 133
  • [38] Deferiprone optimization for the treatment of triple-negative breast cancer
    Johnston, Alexis
    Oyelere, Adegboyega K.
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Updates in the treatment of basal/triple-negative breast cancer
    Shastry, Mythili
    Yardley, Denise A.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2013, 25 (01) : 40 - 48
  • [40] Advances in the Treatment of Triple-negative Early Breast Cancer
    Basso, Stefano M. M.
    Santeufemia, Davide A.
    Fadda, Giovanni M.
    Tozzoli, Renato
    D'Aurizio, Federica
    Lumachi, Franco
    MEDICINAL CHEMISTRY, 2016, 12 (03) : 268 - 272
12345